Ask about this productRelated genes to: MKP4 antibody
- Gene:
- DUSP9 NIH gene
- Name:
- dual specificity phosphatase 9
- Previous symbol:
- -
- Synonyms:
- MKP-4, MKP4
- Chromosome:
- Xq28
- Locus Type:
- gene with protein product
- Date approved:
- 1998-06-25
- Date modifiied:
- 2015-09-11
Related products to: MKP4 antibody
Related articles to: MKP4 antibody
- Head and neck squamous cell carcinoma (HNSCC) exhibits heterogeneous responses to immunotherapy, primarily determined by the tumor immune microenvironment (TME). Accordingly, there is an urgent need for reliable biomarkers that can effectively distinguish between immune "hot" and "cold" tumors and predict prognosis and immunotherapy response. - Source: PubMed
Publication date: 2026/04/08
Li PianPang KelingZhou ZhigangYang ChaolinChen YiWu YangjieWang FujueHe Junyan - Transarterial chemoembolization (TACE) is the primary treatment for unresectable hepatocellular carcinoma (HCC). Given the poor prognosis of liver cancer patients with diabetes, identifying indicators of response to TACE and methods to reverse non-response is crucial. - Source: PubMed
Publication date: 2026/01/21
Wang WeitaoChen KangFan ChenSun LeiTang HaohuanDing WeiSun FeihuWang Weidong - Eradicating leukemia stem cells (LSCs) and overcoming tyrosine kinase inhibitor (TKI) resistance is urgent for chronic myeloid leukemia (CML) treatment. We find that F-box protein 3 (FBXO3) is highly upregulated in CD34 CML stem cells from TKI-resistant patients and identify it as an innovative CML-LSC marker via single-cell RNA sequencing (scRNA-seq). FBXO3 deficiency induces apoptosis and reduces proliferation of CML cell lines and LSCs in vitro and in vivo, with minimal effects on normal CD34 hematopoietic stem cells (HSCs). Mechanistically, FBXO3 interacts with DUSP9 to promote its ubiquitination and activate the MAPK pathway, critical for CML cell activity. DUSP9 knockdown partially reverses FBXO3-deficiency-mediated LSC elimination. Furthermore, FBXO3 inhibitor monotherapy or combination with imatinib effectively eradicates CML-LSCs, overcomes TKI resistance, and spares normal hematopoiesis. Collectively, our findings highlight FBXO3's role in CML progression and support combining FBXO3 inhibitors with TKIs for durable LSC elimination. - Source: PubMed
Li XudongZuo ShiyuZhang YanliLiu ZexingShen NaMa QingqingSun MingxiaZhang BingleiLi MengjiaHuang HongGao MengyaHuang ZhenghuaZhao HuifangChen YilinGao FengcaiFan WenjuanZhang ZhenHu YuhanAn YuLi SiyueLiu MiaoLiu YupengLiu YuxuanLi ChaogeZhang YiguoLi YingmeiCao WeijieWang FangSong YongpingXu LinpingBian ZhileiLi Wei - EZH2 is a histone methyltransferase and a key component of polycomb repressive complex 2 (PRC2). It plays a critical role in genome remodeling, gene regulation and acts through PRC2-dependent and independent mechanisms, which comprise methylation of histone and non-histone substrates, and transcriptional activation through different transcriptional complexes. EZH2 is involved in many cancers, but its role in hepatoblastoma is poorly understood. - Source: PubMed
Publication date: 2026/02/23
Khoubai Fatma ZohraCalovoulos AlexiaGuillorit HélèneCarrillo-Reixach JuanDel Rio-Alvarez AlvaroKlein PierreComa Marina SimonAvignon ChristopheRousseau BenoitMora Charrot LeaFedou SandrineDupuy Jean-WilliamRoyo LauraDomingo-Sàbat MontseThézé NadineSiegfried GéraldineKhatib Abdel-MajidCairo StefanoIndersie EmilieJain Buddhi PrakashTrézéguet VéroniqueGontier EtienneLamoureux FrançoisGuettier CatherineMussini CharlotteHagedorn MartinArmengol CarolinaGrosset Christophe F - Hepatocellular carcinoma (HCC) exhibits pronounced intratumoral heterogeneity largely driven by cancer stem cells (CSCs). However, the molecular regulators that connect CSC stemness to tumor progression remain incompletely understood. - Source: PubMed
Publication date: 2026/01/08
Xu ZhaoyuanZhai XurunLiu MingxinZhang YiCao JiahuiHe JunkaiLi HaoyiLiang RuopengWang WeijieZhu RongtaoSun Yuling